CervoMed is trading at $2.75 (5.8% up), extending its recent rebound from late-July lows amid a broader risk-on market environment.
- The upward move appears aligned with major U.S. indices, which are all trading more than 1% higher today.
- No fresh company-specific news or analyst actions have been reported to serve as a direct catalyst for this session.
- Background sentiment remains supported by June updates regarding clinical trial progress and the company's financial runway.